Leerink Partners Cuts Price Target on TeamHealth Holdings (TMH) After Meeting with Management

August 25, 2016 8:20 AM EDT
Get Alerts TMH Hot Sheet
Price: $43.41 +0.02%

Rating Summary:
    4 Buy, 14 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade TMH Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners maintained an Outperform rating on TeamHealth Holdings (NYSE: TMH), and cut the price target to $40.00 (from $56.00), following the company's 2Q earnings report and management meetings. The company reported a soft 2Q miss on both revenue and EBITDA. Management remains optimistic on the potential for cross-selling synergies from IPC and even the realization of some BPCI synergies by year-end.

Analyst Ana Gupte commented, "We are lowering our PT to $40 for TMH after a weak 2Q and our meetings with Management, Mike Snow (CEO) and David Jones (CFO), in Nashville on Aug. 17, noting risks to 2016 EBITDA achievability across a) 2Q miss and guide-down, b) Slower turnaround of IPC legacy business, and c) leverage ratio that could hamper M&A."

For an analyst ratings summary and ratings history on Team Health click here. For more ratings news on Team Health click here.

Shares of Team Health closed at $34.12 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities


Add Your Comment